The field of resectable melanoma treatment has witnessed recent transformative advances, particularly based on the results of neoadjuvant anti-programmed cell death protein 1 (PD-1)-based immunotherapy trials for resectable macroscopic stage III or IV melanoma.1 Here, PDCD1 is linked to melanoma.